This Commentary article explores the applications of pathway mining for the identification of disease targets associated with breast cancer, where there is an unmet need for treatment. The mission is to identify the best proliferation marker for guiding the choice of systemic treatments for breast cancer.

This commentary article looks at the latest applications in digital and wearable biomarkers, with industry and academic insights from GlaxoSmithKline, Roche, and University College London.

Dr Derek Hill, Professor of Digital Health at University College London, on making the most of digital biomarkers and achieving clinical endpoints.

Video Interview: Caoimhe Vallely-Gilroy, Head of Data Analytics & Strategy, Healthcare, Merck

Workshop Speakers Include: Rhoda Au, Professor of Anatomy & Neurobiology, Neurology and Epidemiology, Boston University School of Medicine | Michael Geer, Co-Founder, Humanity, UK | Dennis Chan, Deputy Lead, EDoN Digital Hub | John Kelley, Chairman and Chief Executive Officer, CereScan |

Claire Huguet, Head of Biomarkers, RANDOX